New hope for elderly lymphoma patients: drug combo targets tough cases
NCT ID NCT07397832
First seen Mar 12, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This study tests a combination of three drugs (chidamide, rituximab, and polatuzumab vedotin) in elderly patients with a specific, hard-to-treat form of diffuse large B-cell lymphoma. The goal is to see how many patients achieve complete remission after treatment. About 58 people aged 60 or older who have not received prior therapy will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Insititute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.